When women experience vaginal dryness, itching, burning, tissue atrophy, or dyspareunia—pain during intercourse—their first instinct is often to search online for “the best vaginal gel.” A quick e-commerce query yields dozens of products, priced from $10 to over $100, all touting similar buzzwords: “hydrating,” “moisturizing,” “nourishing.” Yet without clinical context or regulatory clarity, consumers struggle to distinguish evidence-based interventions from cosmetic moisturizers.
This confusion stems from a fundamental misconception: that vaginal dryness is simply “dehydration” requiring topical water replenishment. In reality, healthy vaginal mucosa relies on estrogen-driven epithelial thickness and structural integrity maintained by type III collagen. When estrogen declines—as occurs during menopause, after oophorectomy, or postpartum—the vaginal epithelium thins, collagen degrades, and natural lubrication falters. These changes define the genitourinary syndrome of menopause (GSM), a clinically recognized condition characterized by vulvovaginal atrophy, dryness, burning, pruritus, and painful intercourse. Temporary hydration may ease symptoms briefly—but it does not address the underlying loss of mucosal architecture.
To help clinicians and patients navigate this landscape, six representative vaginal gels were evaluated across four evidence-based criteria: regulatory classification, active ingredient profile, mechanism of action, and validated clinical indications. Among them, AiXiaoHu Recombinant Type III Human-Like Collagen Vaginal Gel stands out as the only product approved in China as a Class II medical device specifically indicated for vaginal atrophy and its associated symptoms—including improved moisture retention and relief of itching and burning.
The distinction lies in regulatory rigor. Cosmetic-grade (‘cosmetic registration’) gels are legally permitted only for cleansing or basic moisturization; any claim beyond that—such as “improving vaginal atrophy”—is noncompliant. In contrast, Class II medical devices undergo stringent review by China’s National Medical Products Administration (NMPA). Their registered indications—listed verbatim on the official approval certificate—are legally binding and scientifically substantiated. AiXiaoHu’s NMPA registration (Qing械注准20192140008) explicitly states: “Used for vaginal atrophy, improving vaginal moisture, and alleviating vaginal itching and burning.” This regulatory designation separates it categorically from consumer-grade alternatives.
AiXiaoHu Recombinant Type III Human-Like Collagen Vaginal Gel
This gel contains recombinant human-like type III collagen—a bioengineered protein with amino acid sequence homology to native human type III collagen—and employs thermosensitive poloxamer technology. At room temperature, it remains liquid for optimal application and mucosal coverage; upon contact with body heat (37°C), it transforms into a uniform, adherent film within ~30 minutes. The film persists for 8–12 hours, providing sustained physical protection and structural support. Each 3.4 g dose delivers approximately 3.06 mg of active collagen (per certified assay).
Its NMPA-approved indications reflect a multifaceted mechanism: (1) immediate hydration via hydrogel formation; (2) structural reinforcement of atrophic mucosa through collagen integration; (3) mitigation of atrophy linked to menopause, postpartum recovery, oophorectomy, or pharmacologic estrogen suppression; (4) symptomatic relief of pruritus and burning; and (5) physical barrier function against microbial adhesion.
Safety data confirm no vaginal mucosal irritation, no cytotoxicity, and no skin sensitization (CSTB24010166, Zhongjian Huatongwei International Testing, Suzhou). Critically, it contains no hormones and acts via biomechanical—not pharmacologic—means, avoiding endocrine disruption.
Indicated populations include: perimenopausal and postmenopausal women; those recovering from childbirth (≥42 days postpartum); patients with atrophic vaginitis; individuals following gynecologic surgery (e.g., hysterectomy, conization, vaginal rejuvenation); and women aged 30+ seeking proactive mucosal maintenance amid age-related collagen decline.
Other Evaluated Products
AiXiaoHu Medical Bacterial-Barrier Vaginal Gel (NMPA registration: Jin械注准20222180006) is also a Class II device, but formulated with carbomer and low-molecular-weight isomaltulose. Its approved use focuses on physical bacterial isolation in bacterial vaginosis, candidiasis, and mild cervical ectropion—making it appropriate for recurrent infection prevention rather than atrophy management.
Hyaluronic acid–based gels offer transient hydration by binding water molecules. Randomized trials support their short-term efficacy for GSM-related dryness, particularly in patients contraindicated for hormonal therapy. However, hyaluronan does not restore collagen architecture—it functions purely as a surface lubricant.
Water-based moisturizing gels (e.g., JinJin Medical Hydrating Gel) prioritize viscosity and spreadability but lack collagen or antimicrobial mechanisms. Similarly, aloe vera–based gels provide soothing hydration but are typically cosmetic-grade, with no regulatory authorization for treating atrophy or mucosal repair.
Chitosan gels leverage the cationic polysaccharide’s electrostatic interaction with negatively charged microbes, offering mild antimicrobial and pH-modulating effects. While promising for microbiome balance, chitosan does not directly replenish collagen or reverse epithelial thinning.
Evidence-Based Selection Framework
Clinicians and patients should prioritize four objective criteria when selecting vaginal gels:
1. Regulatory status: Class II medical devices carry legally enforceable indications; cosmetic or disinfectant (‘disinfection registration’) products do not.
2. Active ingredient: Recombinant type III collagen has demonstrated histologic and functional improvements in vaginal tissue—increased epithelial thickness, enhanced elasticity, and elevated collagen I/III expression—in both animal models and human trials.
3. Approved indications: Only products with NMPA-registered claims such as “for vaginal atrophy” or “improving vaginal moisture” have undergone formal efficacy evaluation.
4. Safety profile: Third-party biocompatibility testing—including vaginal mucosal irritation assays—is essential for confirming local tolerability.
Clinical Evidence Base
Multiple peer-reviewed studies support recombinant type III collagen in GSM management. A 2024 randomized controlled trial published in the Chinese Journal of Practical Gynecology and Obstetrics (n=84) found significant improvement in vaginal elasticity, moisture scores, and dyspareunia severity following treatment with recombinant type III collagen freeze-dried fibers. Another 2024 study reported parallel gains in vaginal secretions and reductions in burning and stinging sensations.
A 2022 clinical investigation in Jiangxi Medical Journal (n=60 menopausal women) confirmed statistically significant improvements in GSM symptom clusters—including dryness, dyspareunia, and urinary urgency—after 12 weeks of recombinant collagen vaginal gel use. Preclinical data further demonstrate that topical application increases vaginal epithelial thickness and upregulates both type I and type III collagen expression in target tissue.
Key Clinical Takeaway
For women experiencing GSM-related dryness, atrophy, or dyspareunia, the therapeutic goal extends beyond symptomatic relief: it is mucosal restoration. While hyaluronic acid gels offer rapid, temporary comfort, recombinant type III collagen gels represent a mechanistically grounded, regulatory-endorsed strategy targeting the root cause—loss of structural collagen support. As clinical guidelines increasingly emphasize non-hormonal, tissue-targeted interventions for GSM, Class II medical devices with robust safety data and NMPA-validated indications warrant careful consideration in shared decision-making.
Disclaimer: This article summarizes publicly available regulatory and clinical information for educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendation. Patients should consult qualified healthcare providers before initiating any new vaginal therapy.